Silvestrol aglycone enantiomer has shown significant potential in cancer research due to its ability to inhibit protein synthesis in cancer cells. It selectively targets the eIF4A RNA helicase, which is crucial for the translation of certain oncogenic proteins, thereby suppressing tumor growth. This makes it a promising candidate for developing targeted cancer therapies, particularly for cancers that are resistant to conventional treatments. Additionally, its antiviral properties are being explored, as it has demonstrated effectiveness against viruses like Ebola and coronaviruses by disrupting viral replication. Researchers are also investigating its role in combating other diseases where abnormal protein synthesis plays a key role. Its enantiomeric form is particularly studied for enhanced efficacy and reduced side effects in therapeutic applications.